EurekAlert -- Individuals with bipolar disorder are usually treated with ‘mood stabilizing’ drugs, one of which is lithium — an inhibitor of GSK-3 proteins. As new drugs that are more powerful inhibitors of GSK-3 are under development despite controversial studies suggesting a link between lithium therapy and congenital heart defects, Thomas Force and colleagues, at Thomas Jefferson University, Philadelphia, set out to determine whether GSK-3 proteins are important for heart development in mice.